Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for Gastric Cancer Prevention After Endoscopic Resection
KCT0004674Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2020
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Drugs
- aspirin
- Conditions
- gastric cancer (GC)
01
Overview
Phase 3, randomised trial of aspirin in gastric cancer (GC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Feb 2020; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Aspirin prophylaxis
Patients receive aspirin after endoscopic resection for early gastric cancer to prevent new gastric cancers.
Control
Patients undergo standard follow-up after endoscopic resection without aspirin prophylaxis.
03
Who it enrols
Adults with early gastric cancer treated by endoscopic submucosal dissection who are Helicobacter pylori-negative or have successful eradication.
Beyond the preview
Go deeper on KCT0004674.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004674.